Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 5,500 shares of the stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $65.79, for a total transaction of $361,845.00. Following the sale, the insider directly owned 211,148 shares in the company, valued at approximately $13,891,426.92. The trade was a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, January 7th, Carl Dambkowski sold 18,700 shares of Apogee Therapeutics stock. The stock was sold at an average price of $77.84, for a total value of $1,455,608.00.
• On Thursday, December 4th, Carl Dambkowski sold 10,900 shares of Apogee Therapeutics stock. The stock was sold at an average price of $75.00, for a total value of $817,500.00.

Apogee Therapeutics Price Performance

Apogee Therapeutics stock opened at $64.88 on Thursday. The stock has a market capitalization of $4.43 billion, a PE ratio of -14.81 and a beta of 1.42. The business has a 50 day simple moving average of $75.43 and a 200-day simple moving average of $56.13. Apogee Therapeutics Inc. has a 12 month low of $26.20 and a 12 month high of $84.56.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.03. On average, equities research analysts anticipate that Apogee Therapeutics Inc. will post -3.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

APGE has been the topic of several research analyst reports. Craig Hallum reiterated a “buy” rating and issued a $116.00 price objective on shares of Apogee Therapeutics in a report on Wednesday, January 7th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $95.00 price target on shares of Apogee Therapeutics in a research note on Monday. UBS Group raised Apogee Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 7th. Citigroup restated a “buy” rating on shares of Apogee Therapeutics in a report on Sunday, January 25th. Finally, Wolfe Research assumed coverage on shares of Apogee Therapeutics in a report on Wednesday, January 7th. They set a “peer perform” rating for the company. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $104.58.

Institutional Trading of Apogee Therapeutics

Several large investors have recently added to or reduced their stakes in APGE. Lisanti Capital Growth LLC acquired a new stake in shares of Apogee Therapeutics during the 2nd quarter worth approximately $800,000. Fox Run Management L.L.C. acquired a new stake in Apogee Therapeutics during the second quarter worth $437,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Apogee Therapeutics in the 2nd quarter valued at $218,000. Exane Asset Management purchased a new position in shares of Apogee Therapeutics during the 3rd quarter worth $2,048,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Apogee Therapeutics during the 3rd quarter worth about $5,333,000. 79.04% of the stock is currently owned by hedge funds and other institutional investors.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.